Society management

INVO Bioscience will exhibit at the American Society for Reproductive Medicine (ASRM) Congress and Expo 2022

SARASOTA, Florida. and ANAHEIM, Calif., October 17, 2022 /PRNewswire/ — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only intravaginal in vivo culture (IVC) system, INVOcell®an effective and affordable treatment for patients with infertility, today announced that the company will be exhibiting at the 2022 American Society for Reproductive Medicine (ASRM) Scientific Congress and Exhibition to be held October 22-26, 2022 in Anaheim, California at booth #1312.

In the presence of INVO Bioscience will be Steve ShumCEO; Michael CampbellChief Operating Officer and Vice President, Business Development; Chris MyerSenior Vice President, Business Development, Americas; Inger Britt Carlson, PhD, VP, Global Medical Affairs; and Bojan (Bo) MitrovicPhD, Director, Sales, United States.

The ASRM Scientific Congress & Expo is an in-person conference held each October in various cities across the United States. The Society is dedicated to advancing the science and practice of reproductive medicine. It accomplishes its mission through the pursuit of excellence in evidence-based education and lifelong learning, through the advancement and support of innovative research, through the development and dissemination of ethical and quality standards standards of patient care, and by promoting on behalf of Physicians and Affiliated Health Care Providers and their patients.

This year’s Congress offers tracks for Reproductive Endocrinology, Assisted Reproductive Technology, ART Lab, Reproductive Surgery, Mental Health, Nursing, Genetic Counseling, Male Reproduction, and more Again.

Steve ShumCEO of INVO Bioscience, said, “We look forward to further showcasing our innovative INVOcell solution, the world’s first intravaginal culture technique for incubation of oocytes and sperm during fertilization and early embryo development, as well as highlighting our recent business advancements to the reproductive community at ASRM 2022 Congress & Expo. INVO’s mission to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care is fully aligned with the goals and objectives of ASMR. big event this year.”

About INVO Bioscience®

We are a commercial-stage fertility company dedicated to expanding the Assisted Reproductive Technology (“ART”) market by making fertility care accessible and inclusive to people around the world. Our core mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryonic development to take place in vivo in the female body. This treatment solution is the world’s first intravaginal culture technique for incubation of oocytes and sperm during fertilization and early embryo development. This technique, referred to as “IVC”, offers patients a more natural, intimate and affordable experience compared to other ART treatments. We believe the IVC procedure can provide comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”). Our go-to-market strategy is focused on opening dedicated “INVO Centers” offering the INVOcell ® and IVC procedure (with three centers North America now operational), in addition to continuing to distribute and sell our technological solution in existing fertility clinics. For more information, visit www.invobio.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company is relying on the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial condition, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, management plans and objectives for future operations, and statements that include words such as “anticipate”, “if”, “believe”, “plan”, “estimate” , “expect”, “intend”, “may”, “could”, “should”, “should” and other similar expressions are forward-looking statements. All forward-looking statements involve risks , uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anti cipated. Factors that could cause actual results to differ materially from those contained in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation (and expressly disclaim any such obligation) to update or change our forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE INVO Bioscience, Inc.